ShareValue.ai

ShareValue scores for CBL.AU: Valuation 46, Quality 45, Growth 48, Health 50.

CBL.AU
ASX

Control Bionics Ltd

A$0.08(-4.88%)
Loading chart...
Sentiment

Verdicts

Rating

Trap Risk

Return

5% to 16%
Valuation
46
Fair Value
Price vs Value
Quality
45
Moderate
Business Strength
Growth
48
Moderate
Revenue & Earnings
Health
50
Moderate
Financial Stability
Momentum
96
Bullish
Price Trend

Company Details

About

Control Bionics Limited, together with its subsidiaries, engages in the research, development, commercialization, and sale of assistive communications technology systems in Australia, North America, and internationally. It offers NeuroNode Trilogy, NeuroNode Duo, and Eye-gaze Duo systems that allow people with speech and movement difficulties to control a computer for speech generation, electronic communications, entertainment, and external control of other devices. The company also provides the NeuroStrip, a wearable, miniaturized electromyography device; NeuroNode, a wireless, wearable sensor that allows users to access technology through bioelectric signals and spatial movements; and Cosmos Connect, a small portable control device that turns a single NeuroNode sensor into multiple outputs. In addition, it offers mounting systems under the Rehadapt brand, including wheelchair mounts, floor stands, and table stands; switch systems comprising proximity, press, and finger switches; and the autonomous wheelchair module under the DROVE brand. The company was formerly known as Control Bionics Holdings Pty Limited and changed its name to Control Bionics Limited in September 2020. Control Bionics Limited was incorporated in 2005 and is headquartered in Cremorne, Australia.

Score Analysis

AI Investment Thesis

Data as of:Jun 29, 2026
|
Last calculated:Jun 29, 2026